JNJ-73841937, JNJ-73841937 clinical trials

A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tablet Formulations of Lazertinib (JNJ-73841937)

This study is looking at how a new drug, Lazertinib, is absorbed by the body. It’s for healthy adults and compares two different tablet versions of the drug to see if they work the same way. This helps make sure future patients get the best possible treatment.